Literature DB >> 8301214

gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages.

D Pietraforte1, E Tritarelli, U Testa, M Minetti.   

Abstract

The effect of recombinant gp120 HIV envelope glycoprotein on the generation of free radicals by monocyte-derived macrophages (MDM) was measured by EPR spin trapping with 5,5-dimethyl-1-pyrroline-N-oxide (DMPO). After 1 day in culture, MDM produced a spin trap adduct of DMPO with hyperfine splitting constants superimposable on those of DMPO-OH. The addition of gp120 to MDM increased the production of DMPO-OH and after 1 h, the amount of DMPO-OH produced by 40 micrograms/ml gp120 was about 300% that of untreated MDM. The use of selective inhibitors suggested the participation of the nitric oxide/L-arginine oxidative pathway, but did not provide evidence for trapping of hydroxyl radical or other oxygen free radicals. The specificity of gp120 was proven by two different anti-gp120 antibodies that either inhibited (polyclonal) or increased (monoclonal) the production of free radicals. Dexamethasone inhibited the effect of gp120, suggesting the possible involvement of an inducible nitric oxide (NO) synthase. Moreover, treatment of MDM with gp120 for 15 h increased in a dose-dependent manner the production of NO2-, a stable end product of NO. Soluble CD4 did not modify the intensity of the DMPO-OH adduct, whereas yeast mannan and Ca(2+)-chelators abolished the increase in the DMPO-OH signal induced by gp120. These data suggest the possible involvement of mannose-specific endocytotic lectin of MDM. The reaction of DMPO with sodium nitroprusside, an organic nitrate that releases NO, also produced DMPO-OH. Our findings indicate that gp120 increases free radical production from MDM as detected by spin-trapping methods, and that the spin trap adduct results from a reaction involving NO or closely related oxidized derivatives.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301214     DOI: 10.1002/jlb.55.2.175

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  22 in total

1.  Nitric oxide inhibition of coxsackievirus replication in vitro.

Authors:  C Zaragoza; C J Ocampo; M Saura; A McMillan; C J Lowenstein
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Role of IgE immune complexes in the regulation of HIV-1 replication and increased cell death of infected U1 monocytes: involvement of CD23/Fc epsilon RII-mediated nitric oxide and cyclic AMP pathways.

Authors:  F Ouaaz; F W Ruscetti; B Dugas; J Mikovits; H Agut; P Debré; M D Mossalayi
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

3.  Expression of inflammatory cytokines and inducible nitric oxide synthase in brains of SIV-infected rhesus monkeys: applications to HIV-induced central nervous system disease.

Authors:  T E Lane; M J Buchmeier; D D Watry; H S Fox
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

Review 4.  The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995.

Authors:  M P Fink; D Payen
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

5.  Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.

Authors:  David A Davis; Elizabeth Read-Connole; Kara Pearson; Henry M Fales; Fonda M Newcomb; Jackob Moskovitz; Robert Yarchoan
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Nitric oxide synthesis enhances human immunodeficiency virus replication in primary human macrophages.

Authors:  D Blond; H Raoul; R Le Grand; D Dormont
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Serum concentrations of nitrite in patients with HIV-1 infection.

Authors:  D Torre; G Ferrario; F Speranza; A Orani; G P Fiori; C Zeroli
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

8.  CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis.

Authors:  M Hersberger; S Bonhoeffer; S K Rampini; M Opravil; J Marti-Jaun; A Telenti; E Hänseler; B Ledergerber; R F Speck
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 9.  Nitric oxide synthase: expression and expressional control of the three isoforms.

Authors:  U Förstermann; H Kleinert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

Review 10.  HIV-1, reactive oxygen species, and vascular complications.

Authors:  Kristi M Porter; Roy L Sutliff
Journal:  Free Radic Biol Med       Date:  2012-04-21       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.